Chronic Kidney Disease (CKD) affects over 850 million people globally and is a major contributor to cardiovascular morbidity and mortality. High levels of protein in the urine (proteinuria) are both a marker and a driver of kidney damage progression. Despite current therapies like ACE inhibitors and SGLT2 inhibitors, many patients remain at high risk for kidney failure and cardiovascular complications.The D4325C00010 study, sponsored and conducted by AstraZeneca, is a Phase 3, randomized, double-blind, placebo-controlled clinical trial investigating the effectiveness of a novel investigational therapy in slowing the progression of CKD in adults with high proteinuria.